Replies to post #201591 on Biotech Values

[DewDiligence]

SGEN drops Adcetris program in first-line DLBCL:

http://finance.yahoo.com/news/seattle-genetics-presents-data-phase-180000349.html

…based on prioritization of our pipeline, we are discontinuing this [phase-2] trial and have decided not to pursue a registrational pathway for ADCETRIS in frontline DLBCL. We continue to evaluate ADCETRIS in the treatment of relapsed or refractory DLBCL through an ongoing randomized phase 2 trial, as well as more broadly for other CD30-expressing lymphomas, including the ECHELON-1 and ECHELON-2 phase 3 trials in frontline classical Hodgkin lymphoma and frontline mature T-cell lymphoma, respectively.